Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.76 |
| ▸ | NR3C2 | P08235 | 4/20 | 0.76 |
| ▸ | HSD11B2 | P80365 | 3/20 | 0.76 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.76 |
| ▸ | HIF1A | Q16665 | 7/20 | 0.72 |
| ▸ | LMNA | P02545 | 6/20 | 0.72 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.72 |
| ▸ | SHBG | P04278 | 5/20 | 0.72 |
| ▸ | SERPINA6 | P08185 | 5/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.72 |
| ▸ | TSHR | P16473 | 3/20 | 0.72 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.72 |
| ▸ | MAPT | P10636 | 3/20 | 0.72 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.72 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.72 |
| ▸ | BLM | P54132 | 1/20 | 0.72 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.72 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.72 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.72 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20058563 | 1.00 | SMN1; SMN2 (0.76) | SMN1; SMN2NR3C2HSD11B2HSD11B1HIF1A | |
| SCHEMBL13752954 | 1.00 | SMN1; SMN2 (0.76) | SMN1; SMN2NR3C2HSD11B2HSD11B1HIF1A | |
| SCHEMBL10185506 | 1.00 | SMN1; SMN2 (0.76) | SMN1; SMN2NR3C2HSD11B2HSD11B1HIF1A | |
| SCHEMBL15920491 | 1.00 | SMN1; SMN2 (0.76) | SMN1; SMN2NR3C2HSD11B2HSD11B1HIF1A | |
| SCHEMBL3362406 | 1.00 | SMN1; SMN2 (0.76) | SMN1; SMN2NR3C2HSD11B2HSD11B1HIF1A | |
| SCHEMBL619054 | 1.00 | SMN1; SMN2 (0.76) | SMN1; SMN2NR3C2HSD11B2HSD11B1HIF1A | |
| SCHEMBL24900243 | 1.00 | SMN1; SMN2 (0.76) | SMN1; SMN2NR3C2HSD11B2HSD11B1HIF1A | |
| SCHEMBL14525631 | 1.00 | SMN1; SMN2 (0.76) | SMN1; SMN2NR3C2HSD11B2HSD11B1HIF1A | |
| SCHEMBL20058468 | 1.00 | SMN1; SMN2 (0.76) | SMN1; SMN2NR3C2HSD11B2HSD11B1HIF1A | |
| SCHEMBL3235812 | 1.00 | SMN1; SMN2 (0.76) | SMN1; SMN2NR3C2HSD11B2HSD11B1HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260140124-A1 | PCOS STRATIFICATION | THE UNIVERSITY OF BIRMINGHAM (GB) | 2026-05-21 | — | — | US | claimed |
| US-20260042834-A1 | ANTI-CORTICOTROPIN-RELEASING HORMONE ANTIBODIES AND POLYCYSTIC OVARY SYNDROME | HBM ALPHA THERAPEUTICS INC (US) | 2026-02-12 | — | — | US | claimed |
| EP-4387996-A1 | ANTI-CORTICOTROPIN-RELEASING HORMONE ANTIBODIES AND USE IN CONGENITAL ADRENAL HYPERPLASIA | HBM Alpha Therapeutics, Inc. (US) | 2024-06-26 | — | — | EP | claimed |
| WO-2024084250-A1 | PCOS STRATIFICATION | THE UNIVERSITY OF BIRMINGHAM (GB) | 2024-04-25 | — | — | WO | claimed |
| CN-117881697-A | Anti-corticotropin releasing hormone antibodies and their use in congenital adrenocortical hyperplasia | HBM Alpha制药公司 | 2024-04-12 | — | — | CN | claimed |
| WO-2024030906-A2 | ANTI-CORTICOTROPIN-RELEASING HORMONE ANTIBODIES AND POLYCYSTIC OVARY SYNDROME | HBM ALPHA THERAPEUTICS, INC. (US) | 2024-02-08 | — | — | WO | claimed |
| CN-115541776-B | Method for detecting steroid hormone by utilizing high performance liquid chromatography-ion mobility differential mass spectrum | 北京大学第三医院（北京大学第三临床医学院） | 2024-01-19 | — | — | CN | claimed |
| US-11858932-B2 | Methods and compositions for treating polycystic ovary syndrome | SPRUCE BIOSCIENCES, INC. (US) | 2024-01-02 | — | — | US | claimed |
| US-20230322775-A1 | METHODS AND COMPOSITIONS FOR TREATING POLYCYSTIC OVARY SYNDROME | AVENUE CAPITAL MANAGEMENT II, L.P. | 2023-10-12 | — | — | US | claimed |
| US-20230295161-A1 | METHODS AND COMPOSITIONS FOR TREATING POLYCYSTIC OVARY SYNDROME | AVENUE CAPITAL MANAGEMENT II, L.P. | 2023-09-21 | — | — | US | claimed |
| CN-114088859-A | Method for separating multi-component isomer and detecting 29 steroid hormones | 北京金域医学检验实验室有限公司 | 2022-02-25 | — | — | CN | claimed |
| EP-3956669-A1 | METHODS AND SYSTEMS FOR THE DETECTION OF 11-OXO ANDROGENS BY LC-MS/MS | Laboratory Corporation of America Holdings (US) | 2022-02-23 | — | — | EP | claimed |
| US-11208431-B2 | Stable isotope-labeled compounds | ASKA PHARMACEUTIAL CO., LTD. (JP) | 2021-12-28 | — | — | US | claimed |
| CN-113711030-A | Methods and systems for detection of 11-oxoandrogens by LC-MS/MS | 美国控股实验室公司 | 2021-11-26 | — | — | CN | claimed |
| US-20200333361-A1 | Methods and Systems for the Detection of 11-Oxo Androgens by LC-MS/MS | LABORATORY CORPORATION OF AMERICA HOLDINGS | 2020-10-22 | — | — | US | claimed |
| WO-2020214811-A1 | METHODS AND SYSTEMS FOR THE DETECTION OF 11-OXO ANDROGENS BY LC-MS/MS | LABORATORY CORPORATION OF AMERICA HOLDINGS (US) | 2020-10-22 | — | — | WO | claimed |
| EP-3725795-A1 | STABLE-ISOTOPE-LABELED COMPOUND | ASKA Pharmaceutical Co., Ltd. (JP) | 2020-10-21 | — | — | EP | claimed |
| US-20200283469-A1 | STABLE ISOTOPE-LABELED COMPOUNDS | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2020-09-10 | — | — | US | claimed |
| US-20040106216-A1 | Method of measuring drug-metabolizing enzyme activity, method of evaluating inhibition of drug-metabolizing enzyme activity, and composition for these methods | TOYO BOSEKI KABUSHIKI KAISHA (JP) | 2004-06-03 | — | — | US | claimed |
| EP-1378751-A2 | Method of measuring drug-metabolizing enzyme activity, method of evaluating inhibition of drug-metabolizing enzyme activity, and composition for these methods | Toyo Boseki Kabushiki Kaisha (JP) | 2004-01-07 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11858932-B2 | Methods and compositions for treating polycystic ovary syndrome | CYP17A1, SHBG, NR5A1 | SMN1; SMN2 4884/4885NR3C2 26/4885HSD11B2 16/4885 |
| US-11208431-B2 | Stable isotope-labeled compounds | SHBG, AR, NR5A1 | SMN1; SMN2 2549/4885NR3C2 27/4885HSD11B2 16/4885 |
| US-20260042834-A1 | ANTI-CORTICOTROPIN-RELEASING HORMONE ANTIBODIES AND POLYCYSTIC OVARY SYNDROME | CRH, CRHR2, CRHR1 | SMN1; SMN2 4706/4885NR3C2 47/4885HSD11B2 31/4885 |
| US-20260140124-A1 | PCOS STRATIFICATION | HSD17B3, AKR1C3, HSD17B11 | SMN1; SMN2 4876/4885NR3C2 54/4885HSD11B2 24/4885 |
| US-20230322775-A1 | METHODS AND COMPOSITIONS FOR TREATING POLYCYSTIC OVARY SYNDROME | CYP17A1, SHBG, NR5A1 | SMN1; SMN2 4884/4885NR3C2 26/4885HSD11B2 16/4885 |
| US-20230295161-A1 | METHODS AND COMPOSITIONS FOR TREATING POLYCYSTIC OVARY SYNDROME | CYP17A1, SHBG, NR5A1 | SMN1; SMN2 4884/4885NR3C2 26/4885HSD11B2 16/4885 |
| US-20200283469-A1 | STABLE ISOTOPE-LABELED COMPOUNDS | SHBG, AR, NR5A1 | SMN1; SMN2 2549/4885NR3C2 27/4885HSD11B2 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.